Completion of Share Consolidation

16 October 2025: Patrys Limited (ASX: PAB, "Patrys" or the "Company"), a therapeutic antibody development company, is pleased to advise that the consolidation of the issued capital of the Company on a fifteen (15) for one (1) basis, as approved by shareholders at the Annual General Meeting held on 9 October 2025, is now complete (**Consolidation**).

The Company's post-consolidation capital structure is as follows:

Security	**Pre-Consolidation Securities**	**Post-Consolidation Securities***	**Pre-Consolidation Option Exercise Price**	**Post-Consolidation Option Exercise Price**
PAB: Fully Paid Ordinary Shares	4,583,756,578	305,582,502	N/A	N/A
PABAR: Option Expiring 30 September 2026	500,000	33,332	$0.045	$0.675
PABAP: Option Expiring 15 March 2026	2,500,000	166,666	$0.059	$0.885

**Where the consolidation results in a shareholder's account having an entitlement to a fraction of a share or option, the fraction was rounded down to the nearest whole number of shares or options.*

New holding statements are being dispatched to security holders advising them of their security holding on a post-consolidation basis.

Trading on a normal T+2 settlement basis will commence on Wednesday, 22 October 2025.

This announcement is authorised for release by the Board of Directors of Patrys Limited.

For further information, please contact:

General enquiries
Peter Christie
Non-Executive Chair
P: +61 3 9670 3273
info@patrys.com

Registered Office Address
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000

About Patrys Limited
Based in Melbourne, Australia, Patrys (ASX:PAB) is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different indications. More information can be found at www.patrys.com.